Furthermore, Tencent Video has also enhanced its offline benefits for members, including discounts on movie tickets, merchandise, and live events. By expanding the range of perks available to members beyond the online platform, Tencent Video aims to create a more holistic entertainment ecosystem that caters to the diverse interests of its users.
Cricket fans - and even Mitchell Starc - slam Marnus Labuschagne for his wild act during India's Boxing Day Test run chase Marnus Labuschagne was in slips on day five of Test India are facing a record run chase to win seesawing match By JAMES COONEY FOR DAILY MAIL AUSTRALIA and OLIVER CAFFREY AND ROGER VAUGHAN FOR AAP Published: 01:33, 30 December 2024 | Updated: 01:33, 30 December 2024 e-mail View comments Marnus Labuschagne is known for his enthusiasm on the cricket field, but one act has got on supporters' nerves during India 's Boxing Day Test run chase on Monday at the MCG. Labuschagne's gritty half-century drove Australia to a 333-run lead at the close of day four, but the Aussie was annoying fans - and even his teammate Mitchell Starc - with his constant appeals on day five. Numerous times throughout the morning, Labuschagne appealed for wickets that even his teammates didn't believe were a chance of falling. On one occasion, Starc waved Labuschagne and others away after he appealed a caught behind that missed the bat by, what commentators described as, 'a mile'. 'What on Earth is Marnus seeing here,' posted Fox Cricket to social media alongside a clip of the delivery in question. 'Marnus Labuschagne is showing he doesn't have a career post cricket as a test umpire,' wrote another. What on Earth is Marnus seeing here 😂 📺 Watch #AUSvIND LIVE on ch. 501 or stream on Kayo: https://t.co/M7LF1lrubY ✍️ BLOG https://t.co/AWdM6VUdAt 🔢 MATCH CENTRE https://t.co/vbMDJs2dQ5 pic.twitter.com/0UPlyHVwxE — Fox Cricket (@FoxCricket) December 29, 2024 Marnus Labuschagne was roasted by fans for his constant appeals on Monday morning Another posted a photo of a fan holding a sign, saying: 'Marnus free eye & ear checks @Specsavers'. India will need to defy history and the vagaries of the MCG wicket if they are to retain the Border-Gavaskar trophy for a record-extending fifth-straight series. Australia added only a further six runs on Monday after they were bowled out for 234 in the second over of day five, giving them a lead of 339. Nathan Lyon (41) and Scott Boland (15 not out), Australia's No.10 and 11, made 61 in a crucial last-wicket stand that shot the lead past the crucial 300 mark and frustrated India. A bumper crowd is expected to come to the MCG for what could be one of Test cricket's most memorable days. A total of 299,329 fans have already attended this Boxing Day Test, with the all-time MCG record crowd of 350,534 in the 1936-37 Ashes series, when Don Bradman was king, expected to fall. Out-of-form India captain Rohit Sharma will open the batting with young superstar Yashasvi Jaiswal. If India win, they go 2-1 up in the series and as the reigning champions, they will retain the trophy regardless of the fifth Test next week in Sydney. Labuschagne is known for his enthusiasm on the field and love of cricket But the highest successful Test run chase at the ground was nearly a century ago, when England made 7-332 to beat Australia in 1928. If India win, it will be their third-highest Test run chase. It would even beat the 7-329 they posted to win the fourth Test at the Gabba in 2021 and claim the series. Australia's recovery from a shaky 6-91 late on Sunday - also helped by skipper Pat Cummins' 41 - was the latest twist in an epic Test full of momentum swings. Indian superstar Jasprit Bumrah finished with figures of 5-57, giving him nine wickets for the Test and taking him up to 30 for the series. Australia batsman Marnus Labuschagne, who played in the 2021 loss, said that Brisbane wicket was far removed from the MCG pitch. 'As the game has gone on, the bounce has gotten less and more inconsistent,' said Labuschagne, who has impressed in this Test with 72 and 70. 'So we're just getting more balls hitting the stumps, more balls skidding through. Pat Cummins snagged two wickets in a single over on Monday morning 'That makes for pretty tricky batting, because more balls are hitting the stumps from a shorter length. Balls are skidding through (and) a few balls shot up today. 'That wicket (at the Gabba three years ago) was flat ... the main part of the wicket was really nice.' Just as Nitish Kumar Reddy and Washington Sundar turned India's fortunes around on Saturday with their epic eighth-wicket stand, Reddy feels one good partnership on Monday will set up India for the win. Reddy top-scored with 114 in their first innings, his maiden Test ton. 'I feel like you need to get one partnership, one or two good partnerships,' he said. 'We can see later on the fourth day, it (the pitch) was doing a little bit more. 'But we don't need to put on more pressure, like pitches doing this or that. We need to play according to the situations.' Australia's opening bowler Mitch Starc also noted the absorbing contest was the perfect counter to some commentary that Tests should be shortened to four days. 'This why we've got five days for a Test match and really stick it up those who want four days,' he told ABC Radio. India Share or comment on this article: Cricket fans - and even Mitchell Starc - slam Marnus Labuschagne for his wild act during India's Boxing Day Test run chase e-mail Add commentIn a shocking turn of events, a chief prosecutor in Heilongjiang province, China, has allegedly been caught soliciting prostitution. Reports indicate that the prosecutor's resume has been withdrawn from official websites, sparking a wave of speculation and concern. The incident has raised questions about the integrity and conduct of high-ranking officials in the Chinese justice system.However, the situation took an unexpected turn when the man alleged that the woman had organized a lavish banquet in his honor, using his money without his consent. The man expressed shock and dismay at the turn of events, emphasizing that he had only intended to offer a helping hand to a fellow human in need.
Ogun State Governor, Dapo Abiodun, has expressed profound sorrow over the passing of Prince Mahe AbdulKadir, the Chief of Staff to the Kwara State Governor and Chairman of the Nigeria Governors’ Forum, AbdulRahman AbdulRazaq. AbdulKadir reportedly passed away in the early hours of Saturday at the University of Ilorin Teaching Hospital. In a condolence message issued on Saturday in Abeokuta, the Ogun State capital, Abiodun described the death of the Chief of Staff as painful, noting that it represents a significant loss to the Kwara State Executive Council. He emphasised that AbdulKadir’s passing is also a considerable loss to his immediate family and the broader Kwara community, given his unwavering commitment to public service. Abiodun conveyed his sympathies to Governor AbdulRazaq, acknowledging the profound gap left by the death of Prince AbdulKadir. Related News Emir, Kwara speaker mourn gov AbdulRazaq's late chief of staff Kwara gov's Chief of Staff dies at 73 Senator’s billboards removed in Kwara amid rivalry allegations He highlighted the late Chief of Staff’s contributions to the progress and development of Kwara State, adding that his efforts have left an indelible mark on the state and its governance. “Prince AbdulKadir was not only a dedicated public servant but also a humble and hardworking individual whose reliability and dependability were exemplary. His commitment to the betterment of Kwara State was evident in all his undertakings,” Abiodun said. The governor noted that the late Chief of Staff was a significant figure whose strategies and initiatives played a vital role in shaping policies and programmes that benefited the people of Kwara State. “His passing is a reminder of the fragility of life and the importance of cherishing the moments we have with our loved ones,” Abiodun added, as he prayed to Allah to grant the deceased Al-Jannat Firdaus.
Bears general manager Ryan Poles was granted a reprieve complete with a second swing at hiring a head coach in Chicago. Poles will interview candidates and select a replacement for Matt Eberflus, who was fired Friday after the Bears' sixth consecutive loss and fourth of the season decided on a final play. "Ryan Poles is the general manager of the Chicago Bears, and he will remain the general manager of the Chicago Bears," president and CEO Kevin Warren said Monday. "Ryan will serve as the point person of our upcoming search for a head football coach. We will closely, we will work together on a daily basis to make sure we have the right person as our head football coach." Warren said the McCaskey family provided "all the resources" to build a championship environment. He confirmed that Thomas Brown, who a month ago was passing game coordinator before replacing Shane Waldron as offensive coordinator, will serve as interim head coach and shift from the press box to the sideline starting this week. Warren did not say whether Brown would automatically receive an interview for the full-time coaching position, which he said "will be the most coveted head coaching job in the National Football League." Poles said consideration will be given to candidates with the plan to develop rookie No. 1 pick Caleb Williams, but there are no set plans to involve the quarterback in the interview process. He said the Bears showed great progress through two seasons but couldn't sustain growth. "At the end of the day, we just came up short too many times," Poles said of firing Eberflus, his pick to be the Bears' head coach in January 2022. Brown promoted wide receivers coach Chris Beatty to interim offensive coordinator on Monday and announced that defensive coordinator Eric Washington will be the defensive play caller, a role Eberflus previously held. Trailing 23-20 on Thanksgiving Day, the Bears were within field-goal range when quarterback Caleb Williams was sacked. With 32 seconds remaining, Eberflus elected not to use his final timeout as Williams heaved an incompletion down the right sideline as time expired. "When you look at the end-of-the-game situations, detailing to finish in some of those moments. We all know a lot of games come down to those critical moments where we weren't able to get over the hump," Poles said. Eberflus said after the game that everything was handled properly and held a press conference via Zoom on Friday voicing confidence he'd have the team ready to play the 49ers this week. But three hours later, he was fired. Warren admitted the franchise could've handled the timing better, but clarified there was no decision on Eberflus' status at the time of his media session. "The decision was made to terminate the employment of head coach Matt Eberflus," Warren said 72 hours later. "We try to do everything in a professional manner. That decision was made on Friday." "Coach Eberflus had his press conference, we had not made a final decision. I think you know me, you know Ryan you know George McCaskey. One thing we stand for is family, integrity, doing it the right way. In retrospect, could we have done it better? Absolutely." Eberflus, 54, went 14-32 in two-plus seasons. The Bears (4-8) travel to San Francisco (5-7) in Week 1. --Field Level Media
HIVE Digital Technologies Ltd. (NASDAQ:HIVE) Given Consensus Rating of “Buy” by BrokeragesIn response to the emergency, the flight crew quickly accessed the on-board medical kit and oxygen supply to provide assistance to the affected passenger. Despite their efforts, the passenger's condition did not improve, necessitating a diversion to the nearest airport for further medical attention.
Boston College Eagles vs. FDU Knights: How to watch NCAA Basketball online, TV channel, live stream info, start time
None
Despite the challenges facing the money market funds, many experts believe that the current downturn is a temporary phenomenon and that yields are likely to recover in the near future. They point to the strong fundamentals of the financial markets and the overall resilience of the economy as reasons to remain optimistic about the long-term prospects of these funds. However, they caution investors to remain vigilant and to consider diversifying their portfolios to reduce risk and improve returns.As the father continued to pour out his heart to his daughter, reminiscing about the joys and struggles of life, the mother's amusement grew. She knew that her husband's words were spoken in a moment of drunken sincerity, and she found herself both touched by his display of love for their daughter and amused by his melodramatic plea for her to remain by his side forever.ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |